Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 6:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: FDG PET-CT Scan Clear all
Active, not recruiting Phase 2 Interventional

Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)

NCT05564403
View directory record Official record
Conditions
Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma, Advanced Intrahepatic Cholangiocarcinoma, Recurrent Biliary Tract Carcinoma, Recurrent Gallbladder Carcinoma, Recurrent Intrahepatic Cholangiocarcinoma, Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage III Hilar Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Hilar Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Biliary Tract Carcinoma, Unresectable Gallbladder Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
Interventions
Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Echocardiography Test, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Multigated Acquisition Scan, Oxaliplatin
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
207
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 162 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 17, 2026, 6:32 AM EDT
Terminated Phase 2 Interventional Results available

Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer

NCT01022138
View directory record Official record
Conditions
Breast Cancer
Interventions
HER2Bi-armed activated T cells, Cyclophosphamide, Laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Sep 17, 2026, 6:32 AM EDT
Completed Phase 2 Interventional Results available

11C-acetate/18Fluorodeoxyglucose-FDG PET/CT and Cardiac MRI in Pulmonary Hypertension

NCT01917136
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
11C-acetate, [18F]Fluoro-2-deoxy-2-D-glucose, Cardiac MRI
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Sep 17, 2026, 6:32 AM EDT
Withdrawn Phase 1 Interventional

CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT05950113
View directory record Official record
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine, Fludeoxyglucose F-18, Immunotherapy, Leukapheresis, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 74 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Sep 17, 2026, 6:32 AM EDT
Completed No phase listed Observational

Positron Emission Tomography for the Diagnosis of Immune Checkpoint Inhibitor-Related Myocarditis

NCT05062395
View directory record Official record
Conditions
Myocarditis Acute
Interventions
Computed Tomography, Fludeoxyglucose F-18, Low Carbohydrate High Fat Diet, Positron Emission Tomography
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2023 · Synced Sep 17, 2026, 6:32 AM EDT
Completed Not applicable Interventional

PET Scans in Diagnosing Primary or Recurrent Cervical Cancer in Patients Who Are Undergoing Surgery

NCT00003429
View directory record Official record
Conditions
Cervical Cancer
Interventions
biopsy, computed tomography, positron emission tomography, fludeoxyglucose F 18
Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2015 · Synced Sep 17, 2026, 6:32 AM EDT
Completed Not applicable Interventional Results available

Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI

NCT00537056
View directory record Official record
Conditions
Kidney Neoplasms, Carcinoma, Renal Cell, Kidney (Renal Cell) Cancer
Interventions
FDG PET CT, DCE MRI, F-18 Fluoro-deoxi-glucose, Gadolinium-DTPA, Sunitinib
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 17, 2026, 6:32 AM EDT
Not listed Not applicable Interventional

Validating Low FDG Dose PET/CT Compared to Current Standard of Care Dose PET/CT

NCT03519659
View directory record Official record
Conditions
PET/CT Imaging
Interventions
PET/CT scan with 13 mCi radiation dose, PET/CT scan with 5 mCi radiation dose, PET/CT scan with 2.5 mCi radiation dose, PET/CT Scan with 6.5 mCi radiation dose, PET/CT Scan with not yet determined radiation dose
Diagnostic Test
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Sep 17, 2026, 6:32 AM EDT
Completed Phase 2 Interventional

A Study of Xevinapant With Cisplatin and Radiation Therapy After Surgery in People With Head and Neck Cancer

NCT06145412
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Xevinapan, Cisplatin, External beam
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 17, 2026, 6:32 AM EDT
Terminated Not applicable Interventional

Breathing Synchronized PET/CT Scans for the Detection of Malignant Lung & Liver Lesions and Assessment of Tumor Glycolysis

NCT01052766
View directory record Official record
Conditions
Lung Cancer, Non-small Cell Lung Cancer
Interventions
PET/CT and BH PET/CT
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Sep 17, 2026, 6:32 AM EDT
Completed Phase 2 Interventional Results available

Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma

NCT00737438
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Sep 17, 2026, 6:32 AM EDT
Completed No phase listed Observational

PET/CT in Psoriatic Arthritis

NCT01654198
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
FDG-PET/CT scan
Radiation
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Sep 17, 2026, 6:32 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

FDG PET/MR Imaging of Peripheral Pain Generators

NCT06171659
View directory record Official record
Conditions
Pain, Nociceptive Pain
Interventions
FDG radiotracer, PET/MRI, PET/CT imaging
Drug · Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 85 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 17, 2026, 6:32 AM EDT
Completed Phase 2 Interventional Results available

F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer

NCT00602043
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
F-18 16 alpha-fluoroestradiol, fludeoxyglucose F 18, positron emission tomography, computed tomography, laboratory biomarker analysis
Radiation · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Sep 17, 2026, 6:32 AM EDT
Recruiting Phase 1 Interventional

Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF

NCT03604315
View directory record Official record
Conditions
Breast Carcinoma, Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Solid Neoplasm
Interventions
Computed Tomography, Fludeoxyglucose F-18, Fluorine F 18 Fluorthanatrace, Positron Emission Tomography
Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 17, 2026, 6:32 AM EDT
Recruiting Phase 1 Interventional

Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma

NCT05892393
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Myeloma
Interventions
Zirconium Zr 89-DFO-YS5, Positron Emission Tomography / Computed Tomography (PET/CT), Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI), Fludeoxyglucose F-18
Drug · Procedure · Other
Lead sponsor
Robert Flavell, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 17, 2026, 6:32 AM EDT
Completed Phase 1 Interventional

Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

NCT01561014
View directory record Official record
Conditions
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach, Squamous Cell Carcinoma of the Esophagus, Stage II Esophageal Cancer, Stage II Gastric Cancer, Stage III Esophageal Cancer, Stage III Gastric Cancer
Interventions
erlotinib hydrochloride, oxaliplatin, fluorouracil, radiation therapy, conventional surgery, immunohistochemistry staining method, positron emission tomography, computed tomography, laboratory biomarker analysis, gene expression analysis, fludeoxyglucose F 18
Drug · Radiation · Procedure + 2 more
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Sep 17, 2026, 6:32 AM EDT
Completed Phase 2 Interventional Results available

Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer

NCT03416153
View directory record Official record
Conditions
Oropharynx Cancer
Interventions
Carboplatin, Radiation Therapy, Paclitaxel
Drug · Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 17, 2026, 6:32 AM EDT
Recruiting Phase 2 Interventional

Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma

NCT04965454
View directory record Official record
Conditions
Hepatocellular Carcinoma Non-resectable
Interventions
Fluorine-18 fluorocholine
Combination Product
Lead sponsor
Queen's Medical Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 17, 2026, 6:32 AM EDT
Active, not recruiting Phase 2 Interventional

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

NCT05198830
View directory record Official record
Conditions
Lung Adenocarcinoma, Lung Large Cell Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8
Interventions
Carboplatin, Cisplatin, Computed Tomography, Durvalumab, FDG-Positron Emission Tomography, Magnetic Resonance Imaging, Methoxyamine, Pemetrexed, Radiation Therapy
Drug · Procedure · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
34
States / cities
Buena Park, California • Duarte, California • Irvine, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 17, 2026, 6:32 AM EDT
Completed Phase 4 Interventional Results available

Vascular Inflammation in Psoriasis - Extension Study

NCT01866592
View directory record Official record
Conditions
Psoriasis, Cardiovascular Disease
Interventions
Adalimumab
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
9
States / cities
Sacramento, California • Denver, Colorado • Bethesda, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Sep 17, 2026, 6:32 AM EDT
Completed Phase 2 Interventional Results available

Imaging in MGUS, SMM and MM

NCT01237054
View directory record Official record
Conditions
Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Interventions
18-NaF PET, DCE-MRI, 18-FDG PET/CT
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 17, 2026, 6:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Relationship Between Down Syndrome (DS) and Alzheimer's Disease (AD)

NCT02759887
View directory record Official record
Conditions
Down Syndrome, Alzheimer's Dementia
Interventions
biospecimen collection, cognitive assessments, caregiver questionnaire, Florbetapir F18 imaging, MRI, Fludeoxyglucose F18 (FDG), Tau Pet, Actigraphy
Procedure · Other
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
21 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Sep 17, 2026, 6:32 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Hyperpolarized 13C Pyruvate-MRI and FDG-PET in a Single Exam for the Prognosis of Ischemic Cardiomyopathy

NCT06814587
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Bypass Graft (CABG)
Interventions
Hyperpolarized 13C Pyruvate Magnetic Resonance Imaging (HP-13C MRI), [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography (FDG-PET), SPECT MPI (Single Photon Emission Computed Tomography Myocardial Perfusion Imaging)
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
20 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 17, 2026, 6:32 AM EDT